How a big pharma company stalled a potentially lifesaving vaccine in pursuit of bigger profits

A vaccine against tuberculosis, the world’s deadliest infectious disease, has never been closer to reality, with the potential to save millions of lives. But its development slowed after its corporate owner focused on more profitable vaccines.

Related Keywords

United States ,Chile ,United Kingdom ,National Institutes Of Health ,Maryland ,South Africa ,Thailand ,Philadelphia ,Pennsylvania ,Brazil ,Australia ,Netherlands ,Montana ,Rockville ,Chilean ,South African ,America ,Luc Debruyne ,Mike Frick ,Jeremy Farrar ,Thomas Scriba ,Glenda Gray ,Tom Evans ,Thomas Breuer ,Wolfgang Leitner ,Smithkline Beckman ,Julio Croda ,Paul Sagan ,Carl Alving ,Neil Martinson ,Emma Walmsley ,Steven Reed ,Us Army ,Cornell University ,Department Of Veterans Affairs ,Walter Reed Army Institute Of Research ,World Health Organization ,National Institute Of Allergy ,Drug Administration ,Wellcome ,Melinda Gates Foundation ,Gates Foundation ,Tb Vaccine Accelerator Council ,Treatment Action Group ,Melinda Gates Medical Research Institute ,Pulitzer Prize Winning ,Big Story ,Big Pharma ,Walter Reed Army Institute ,Veterans Affairs ,National Institutes ,Michel De Wilde ,Wellcome Trust ,South America ,Eastern Europe ,Accelerator Council ,National Institute ,Infectious Diseases ,Treatment Action ,